2,195 reports of this reaction
4.4% of all CANAGLIFLOZIN reports
#2 most reported adverse reaction
TOE AMPUTATION is the #2 most commonly reported adverse reaction for CANAGLIFLOZIN, manufactured by Janssen Pharmaceuticals, Inc.. There are 2,195 FDA adverse event reports linking CANAGLIFLOZIN to TOE AMPUTATION. This represents approximately 4.4% of all 49,711 adverse event reports for this drug.
Patients taking CANAGLIFLOZIN who experience toe amputation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
TOE AMPUTATION is moderately reported among CANAGLIFLOZIN users, representing a notable but not dominant share of adverse events.
In addition to toe amputation, the following adverse reactions have been reported for CANAGLIFLOZIN:
TOE AMPUTATION has been reported as an adverse event in 2,195 FDA reports for CANAGLIFLOZIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
TOE AMPUTATION accounts for approximately 4.4% of all adverse event reports for CANAGLIFLOZIN, making it one of the most commonly reported side effect.
If you experience toe amputation while taking CANAGLIFLOZIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.